CN101502641A - 一种注射给药的环孢素药物组合物 - Google Patents
一种注射给药的环孢素药物组合物 Download PDFInfo
- Publication number
- CN101502641A CN101502641A CNA2009101032418A CN200910103241A CN101502641A CN 101502641 A CN101502641 A CN 101502641A CN A2009101032418 A CNA2009101032418 A CN A2009101032418A CN 200910103241 A CN200910103241 A CN 200910103241A CN 101502641 A CN101502641 A CN 101502641A
- Authority
- CN
- China
- Prior art keywords
- ciclosporin
- injection
- peg
- polysorbate
- solutol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title claims abstract description 117
- 108010036949 Cyclosporine Proteins 0.000 title claims abstract description 117
- 229960001265 ciclosporin Drugs 0.000 title claims abstract description 117
- 238000002347 injection Methods 0.000 title claims abstract description 88
- 239000007924 injection Substances 0.000 title claims abstract description 88
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims abstract description 17
- JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229920001304 Solutol HS 15 Polymers 0.000 claims abstract description 29
- 239000002904 solvent Substances 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000008215 water for injection Substances 0.000 claims abstract description 9
- 238000001647 drug administration Methods 0.000 claims abstract description 8
- 150000002148 esters Chemical class 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 150000001298 alcohols Chemical class 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 63
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 18
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 17
- 229930195725 Mannitol Natural products 0.000 claims description 17
- 239000000594 mannitol Substances 0.000 claims description 17
- 235000010355 mannitol Nutrition 0.000 claims description 17
- 239000002202 Polyethylene glycol Substances 0.000 claims description 14
- 229920001223 polyethylene glycol Polymers 0.000 claims description 14
- -1 15-hydroxy stearic acid ester Chemical class 0.000 claims description 13
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 13
- 239000006184 cosolvent Substances 0.000 claims description 12
- 229920001219 Polysorbate 40 Polymers 0.000 claims description 11
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims description 11
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims description 11
- 229940101027 polysorbate 40 Drugs 0.000 claims description 11
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 9
- 239000000194 fatty acid Substances 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 150000004665 fatty acids Chemical class 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 239000005864 Sulphur Substances 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 229920000136 polysorbate Polymers 0.000 claims description 4
- 229950008882 polysorbate Drugs 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 2
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 claims description 2
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 claims description 2
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 229920002642 Polysorbate 65 Polymers 0.000 claims description 2
- JVFGXECLSQXABC-UHFFFAOYSA-N ac1l3obq Chemical compound O1C(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(O)C2O)C(COCC(O)C)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC2C(O)C(O)C1OC2COCC(C)O JVFGXECLSQXABC-UHFFFAOYSA-N 0.000 claims description 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 2
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 claims description 2
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 claims description 2
- 229940068977 polysorbate 20 Drugs 0.000 claims description 2
- 229940113124 polysorbate 60 Drugs 0.000 claims description 2
- 229940099511 polysorbate 65 Drugs 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 20
- 238000005516 engineering process Methods 0.000 abstract description 15
- 206010002198 Anaphylactic reaction Diseases 0.000 abstract description 9
- 208000003455 anaphylaxis Diseases 0.000 abstract description 9
- 238000004519 manufacturing process Methods 0.000 abstract description 8
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 7
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 abstract description 7
- 239000008389 polyethoxylated castor oil Substances 0.000 abstract description 7
- 238000003908 quality control method Methods 0.000 abstract description 2
- 229940072106 hydroxystearate Drugs 0.000 abstract 1
- 239000008176 lyophilized powder Substances 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 description 22
- 239000000843 powder Substances 0.000 description 19
- 229960004756 ethanol Drugs 0.000 description 15
- 229960000935 dehydrated alcohol Drugs 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 6
- 230000036783 anaphylactic response Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 230000002052 anaphylactic effect Effects 0.000 description 2
- 230000000919 anti-host Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 208000012904 Bartter disease Diseases 0.000 description 1
- 208000010062 Bartter syndrome Diseases 0.000 description 1
- 206010051779 Bone marrow toxicity Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000013633 acquired hemophilia Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 231100000366 bone marrow toxicity Toxicity 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011082 depyrogenation Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000002089 myocardial stunning Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101032418A CN101502641B (zh) | 2009-02-23 | 2009-02-23 | 一种注射给药的环孢素药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101032418A CN101502641B (zh) | 2009-02-23 | 2009-02-23 | 一种注射给药的环孢素药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101502641A true CN101502641A (zh) | 2009-08-12 |
CN101502641B CN101502641B (zh) | 2012-05-02 |
Family
ID=40975104
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009101032418A Expired - Fee Related CN101502641B (zh) | 2009-02-23 | 2009-02-23 | 一种注射给药的环孢素药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101502641B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105646672A (zh) * | 2014-12-04 | 2016-06-08 | 石家庄中天生物技术有限责任公司 | 高纯度4-羟基环孢素及其提纯制备方法 |
CN109906085A (zh) * | 2016-09-23 | 2019-06-18 | 诺瓦利克有限责任公司 | 含有环孢素的眼用组合物 |
CN112957450A (zh) * | 2019-12-20 | 2021-06-15 | 艾棣维欣(苏州)生物制药有限公司 | 一种难溶性药物的水溶液及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19549852B4 (de) * | 1995-11-29 | 2009-06-04 | Novartis Ag | Cyclosporin enthaltende Präparate |
CN1167462C (zh) * | 1999-03-09 | 2004-09-22 | 杭州华东医药集团生物工程研究所有限公司 | 一种含环孢素的药物组合物 |
-
2009
- 2009-02-23 CN CN2009101032418A patent/CN101502641B/zh not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105646672A (zh) * | 2014-12-04 | 2016-06-08 | 石家庄中天生物技术有限责任公司 | 高纯度4-羟基环孢素及其提纯制备方法 |
CN109906085A (zh) * | 2016-09-23 | 2019-06-18 | 诺瓦利克有限责任公司 | 含有环孢素的眼用组合物 |
CN109906085B (zh) * | 2016-09-23 | 2024-03-08 | 诺瓦利克有限责任公司 | 含有环孢素的眼用组合物 |
CN112957450A (zh) * | 2019-12-20 | 2021-06-15 | 艾棣维欣(苏州)生物制药有限公司 | 一种难溶性药物的水溶液及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101502641B (zh) | 2012-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101502533B1 (ko) | 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법 | |
AU2005227421B2 (en) | Formulations | |
CA2595617C (en) | Formulations for injection of catecholic butanes, including ndga compounds, into animals | |
EP2019664B1 (en) | Stable pharmaceutical composition containing docetaxel and a method of manufacturing the same | |
US8304450B2 (en) | Stable pharmaceutical compositions with docetaxel | |
CN101366696B (zh) | 一种紫杉醇的水溶性注射用药物组合物、制备方法及用途 | |
CN105640886A (zh) | 一种西罗莫司自微乳制剂及其制备方法 | |
CN101502641B (zh) | 一种注射给药的环孢素药物组合物 | |
US8481589B2 (en) | Taxoid-based compositions | |
US6008191A (en) | Pharmaceutical compositions containing cyclosporin | |
CN102481287B (zh) | 含维生素c或其衍生物的替莫唑胺药物组合物及其制备方法 | |
EP0982035A1 (en) | Cyclosporin composition comprising an hydrophilic carrier | |
AU716855B2 (en) | Novel compositions containing cyclosporin | |
CN101199530A (zh) | 伊曲康唑纳米混悬剂冻干组合物及其制备和使用方法 | |
Wang et al. | Self-micro-Emulsifying controlled release of eugenol pellets: Preparation, in vitro/in vivo investigation in beagle dogs | |
CN1853627B (zh) | 双苯并异硒唑乙烷环糊精或环糊精衍生物包合物及其制备方法和其用途 | |
CN102670579A (zh) | 一种紫杉醇药物组合物及其制备方法 | |
CN1744917B (zh) | 经肺给药用缓释性制剂学组合物 | |
CN106619541A (zh) | 艾沙康唑鎓硫酸盐冻干粉针剂及制备方法 | |
CN101181284A (zh) | 注射用伊曲康唑冻干组合物及制备方法 | |
CN104146966B (zh) | 一种度他雄胺自微乳冻干组合物及其制备方法 | |
AU762963B2 (en) | Cyclosporin solution | |
WO2019047812A1 (zh) | 多西他赛共缀物的药物组合物及制备方法 | |
WO2007142440A1 (en) | Stable pharmaceutical composition containing paclitaxel and a method of manufacturing the same | |
WO2017037232A1 (en) | Anidulafungin formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C53 | Correction of patent of invention or patent application | ||
C56 | Change in the name or address of the patentee | ||
CB03 | Change of inventor or designer information |
Inventor after: Liu Hong Inventor after: Pan Hongchun Inventor after: Yao Dingquan Inventor after: Zheng Wei Inventor before: Yao Dingquan |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: YAO DINGQUAN TO: LIU HONG PAN HONGCHUN YAO DINGQUAN ZHENG WEI |
|
CP02 | Change in the address of a patent holder |
Address after: 1 unit 1, building 41, 400054 Garden Street, Rongchang County, Chongqing, 5-1 Patentee after: Yao Dingquan Address before: Room 3, unit 89, Huilong Plaza, 1701 South Kun Road, Hainan, Haikou, 570000 Patentee before: Yao Dingquan |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120502 |
|
CF01 | Termination of patent right due to non-payment of annual fee |